Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors in the central nervous technique, conolidine modulates alternate molecular targets. A Science Developments review found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://proleviate-uses-fda-appro21098.bloggosite.com/46808185/conolidin-to-replace-traditional-painkillers-fundamentals-explained